Long‐Term Outcomes of Renal Transplant Allografts With De Novo DSA in the Setting of Stable Function
- 21 May 2026
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 40 (5) , e70576
Abstract
Background: We sought to determine the long‐term outcomes of renal allografts that developed de novo DSA (dnDSA) in the setting of stable function. Methods: This retrospective single‐center review of renal allograft recipients transplanted between January 2008 and December 2011. DnDSA testing was performed at 3, 6, 9, and 12 months and yearly thereafter. Results: The study included 501 recipients; 84% primary transplants, and 37% living donors. The median follow‐up duration was 110 (range 9–157) months. One hundred fifty‐seven (31%) recipients developed dnDSA, and the median time to the first dnDSA was 18 (range 3–144) months. Death‐censured graft survival in recipients with no DSA was significantly better than that of dnDSA‐positive recipients. There were 344 recipients with no DSA (group 1), 117 recipients with dnDSA and stable graft function (group 2), and 40 recipients with dnDSA‐associated acute rejection (group 3). Death‐censured graft survival was equivalent between groups 1 and 2 and significantly better than that in group 3. Seventy‐eight percent of Group 3 lost their grafts at a median of 56 (range 12–137) months posttransplant. Group 2 recipients had an increased incidence of late acute rejection compared to group 1 ( p < 0.001), yet the mean eGFR values of both groups were equivalent at one, 5, and, 10 years posttransplantation ( p > 0.05). Conclusions: Development of dnDSA in recipients with stable graft function increased the risk of late acute rejection, but had no detrimental impact on long‐term graft survival or function. De novo DSA, associated with acute rejection, generally resulted in long‐term graft loss.Keywords
This publication has 16 references indexed in Scilit:
- Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant CohortTransplantation, 2019
- Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric StudyTransplantation, 2019
- Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant RecipientsTransplantation, 2018
- Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft FailureTransplantation, 2018
- Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal TransplantationTransplantation, 2017
- De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft InjuryTransplantation, 2016
- Intermediate-Term Graft Loss After Renal Transplantation is Associated With Both Donor-Specific Antibody and Acute RejectionTransplantation, 2014
- Complement-Binding Anti-HLA Antibodies and Kidney-Allograft SurvivalNew England Journal of Medicine, 2013
- Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal AllograftsTransplantation, 2013
- Inferior Kidney Allograft Outcomes in Patients With De Novo Donor-Specific Antibodies Are Due to Acute Rejection EpisodesTransplantation, 2011